High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions
Biotechnology Progress · 2024
DOI: 10.1002/btpr.3445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2024. Verfasst von Louis Coplan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Manufacturing and Process Development, Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Vectors, Transfection, Bioreactors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals, Regeneron Preclinical Manufacturing and Process Development.
Abstract (Originalsprache)
Recombinant adeno‐associated viral vectors (rAAVs) are one of the most used vehicles for gene therapy, with five rAAV therapeutics commercially approved by the FDA. To improve product yield, we optimized the suspension production process of rAAV8 vectors carrying a proprietary transgene using a commercially available transfection reagent, FectoVIR‐AAV. Using a miniaturized automated 250 mL scale bioreactor system, we generated models of vector genome (vg) titer, capsid (cp) titer, and Vg:Cp percentage from two multivariate design of experiment studies, one centered around bioreactor operating parameters, and another based on the transfection conditions. Using the optimized process returned from these models, the vector genome titer from the bioreactor was improved to beyond 1 × 10 12 vg/mL. Five critical parameters were identified that had large effects on the pre‐purification vector quantity—the transfection pH, production pH, complexation time, viable cell density at transfection, and transfection reagent to DNA ratio. The optimized process was further assessed for its performance extending to six AAV serotypes, namely AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 carrying a transgene encoding for green fluorescent protein (GFP). Five of the six serotypes returned higher vector genome titers than the control condition. These data suggest that the choice of transfection reagent is a major factor in improving vector yield. The multivariate design of experiment approach is a powerful way to optimize production processes, and the optimized process from one AAV vector can to some extent be generalized to other serotypes and transgenes to accelerate development timelines of new programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Preclinical Manufacturing and Process Development, Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.
- Department of Chemical & Biomolecular Engineering, University of Maryland, College Park, Maryland, USA.
- Research Operations, Regeneron Pharmaceuticals Inc, Tarrytown, New York, USA.
ORCID-Profile: Louis Coplan, Andrew D Tustian
Förderung
- Regeneron Pharmaceuticals
- Regeneron Preclinical Manufacturing and Process Development
Zitieren
APA
Coplan, L., Zhang, Z., Ragone, N., Reeves, J., Rodriguez, A., Shevade, A., Bak, H., & Tustian, A. D. (2024). High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions. Biotechnology Progress. https://doi.org/10.1002/btpr.3445
Vancouver
Coplan L, Zhang Z, Ragone N, Reeves J, Rodriguez A, Shevade A, et al. High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions. Biotechnology Progress. 2024. doi:10.1002/btpr.3445
BibTeX
@article{Coplan2024,
author = {Coplan, Louis and Zhang, Zhe and Ragone, Nicole and Reeves, John and Rodriguez, Audrey and Shevade, Aishwarya and Bak, Hanne and Tustian, Andrew D},
title = {High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions},
journal = {Biotechnology Progress},
year = {2024},
doi = {10.1002/btpr.3445}
}
EUVIMED